-
1
-
-
54849381700
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
-
Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175-187.
-
(2008)
Schizophr Res.
, vol.105
, pp. 175-187
-
-
Daumit, G.L.1
Goff, D.C.2
Meyer, J.M.3
-
2
-
-
26644445926
-
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks andmortality: Results of a 10-year naturalistic study
-
Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks andmortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
-
(2005)
J Clin Psychiatry.
, vol.66
, pp. 1116-1121
-
-
Henderson, D.C.1
Nguyen, D.D.2
Copeland, P.M.3
-
3
-
-
79952273080
-
Antipsychotics and metabolics in the post-CATIE era
-
Meyer JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010;4:23-42.
-
(2010)
Curr Top Behav Neurosci.
, vol.4
, pp. 23-42
-
-
Meyer, J.M.1
-
4
-
-
84912541812
-
Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis
-
Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophr Bull. 2014;40:1385-1403.
-
(2014)
Schizophr Bull.
, vol.40
, pp. 1385-1403
-
-
Mizuno, Y.1
Suzuki, T.2
Nakagawa, A.3
-
5
-
-
84883728317
-
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder
-
Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170:1032-1040.
-
(2013)
Am J Psychiatry.
, vol.170
, pp. 1032-1040
-
-
Jarskog, L.F.1
Hamer, R.M.2
Catellier, D.J.3
-
6
-
-
84941282320
-
Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials
-
ZhengW, Li XB, Tang YL, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35: 499-509.
-
(2015)
J Clin Psychopharmacol.
, vol.35
, pp. 499-509
-
-
Zheng, W.1
Li, X.B.2
Tang, Y.L.3
-
7
-
-
84998166021
-
Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials
-
Praharaj SK, Sharma PS. Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2012;2:151-156.
-
(2012)
Ther Adv Psychopharmacol.
, vol.2
, pp. 151-156
-
-
Praharaj, S.K.1
Sharma, P.S.2
-
8
-
-
84880133046
-
NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials
-
Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013;47:1143-1149.
-
(2013)
J Psychiatr Res.
, vol.47
, pp. 1143-1149
-
-
Kishi, T.1
Iwata, N.2
-
9
-
-
0036750803
-
Amantadine treatment of psychotropic-induced weight gain in children and adolescents: Case series
-
Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol. 2002;12:249-257.
-
(2002)
J Child Adolesc Psychopharmacol.
, vol.12
, pp. 249-257
-
-
Gracious, B.L.1
Krysiak, T.E.2
Youngstrom, E.A.3
-
10
-
-
0023154937
-
Amantadine in the treatment of neuroendocrine side effects of neuroleptics
-
Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7:91-95.
-
(1987)
J Clin Psychopharmacol.
, vol.7
, pp. 91-95
-
-
Correa, N.1
Opler, L.A.2
Kay, S.R.3
-
11
-
-
0035063715
-
Effect of amantadine onweight gain during olanzapine treatment
-
FlorisM, Lejeune J, DeberdtW. Effect of amantadine onweight gain during olanzapine treatment. Eur Neuropsychopharmacol. 2001;11:181-182.
-
(2001)
Eur Neuropsychopharmacol.
, vol.11
, pp. 181-182
-
-
Floris, M.1
Lejeune, J.2
Deberdt, W.3
-
13
-
-
24944539629
-
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
-
Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744-1746.
-
(2005)
Am J Psychiatry.
, vol.162
, pp. 1744-1746
-
-
Graham, K.A.1
Gu, H.2
Lieberman, J.A.3
-
14
-
-
85018232981
-
A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia [In Chinese]
-
JiWJ, Jiang X, Chen HY, et al. A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia [In Chinese]. J Clin Psychiatry. 2014;24:1-3.
-
(2014)
J Clin Psychiatry.
, vol.24
, pp. 1-3
-
-
Ji, W.J.1
Jiang, X.2
Chen, H.Y.3
-
15
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
-
(1987)
Schizophr Bull.
, vol.13
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
16
-
-
0000503515
-
The brief psychiatric rating scale
-
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
-
(1962)
Psychol Rep.
, vol.10
, pp. 799-812
-
-
Overall, J.E.1
Gorham, D.R.2
-
19
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
-
(2002)
Stat Med.
, vol.21
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
20
-
-
78651415131
-
Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study
-
Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271-275.
-
(2010)
Clin Neuropharmacol.
, vol.33
, pp. 271-275
-
-
Pappa, S.1
Tsouli, S.2
Apostolou, G.3
-
21
-
-
26944441259
-
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients
-
Silver H, Goodman C, Isakov V, et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol. 2005;20:319-326.
-
(2005)
Int Clin Psychopharmacol.
, vol.20
, pp. 319-326
-
-
Silver, H.1
Goodman, C.2
Isakov, V.3
-
22
-
-
0030922816
-
Bias in meta-analysis detected by a simple, graphical test
-
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
-
(1997)
BMJ.
, vol.315
, pp. 629-634
-
-
Egger, M.1
Davey Smith, G.2
Schneider, M.3
-
25
-
-
84974793861
-
Grading quality of evidence and strength of recommendations
-
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
-
(2004)
BMJ.
, vol.328
, pp. 1490
-
-
Atkins, D.1
Best, D.2
Briss, P.A.3
-
26
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12.
-
(1996)
Control Clin Trials.
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
-
27
-
-
0030995082
-
A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia
-
Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.JClin Psychopharmacol. 1997;17:88-91.
-
(1997)
JClin Psychopharmacol.
, vol.17
, pp. 88-91
-
-
Angus, S.1
Sugars, J.2
Boltezar, R.3
-
28
-
-
84942368577
-
Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics
-
Czepielewski LS, Sodré L, Souza AC, et al. Changes in verbal learning of patients with schizophrenia: results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics. Schizophr Res. 2015;168:571-572.
-
(2015)
Schizophr Res.
, vol.168
, pp. 571-572
-
-
Czepielewski, L.S.1
Sodré, L.2
Souza, A.C.3
-
29
-
-
0030990693
-
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies
-
DanyszW, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 1997;21:455-468.
-
(1997)
Neurosci Biobehav Rev.
, vol.21
, pp. 455-468
-
-
Danysz, W.1
Parsons, C.G.2
Kornhuber, J.3
-
30
-
-
0028170903
-
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
-
Kornhuber J,WellerM, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91-104.
-
(1994)
J Neural Transm Suppl.
, vol.43
, pp. 91-104
-
-
Kornhuber, J.1
Weller, M.2
Schoppmeyer, K.3
-
31
-
-
0030470687
-
Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: Evidence from a double-blind crossover study
-
Silver H,Geraisy N. Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol. 1996;16:463-464.
-
(1996)
J Clin Psychopharmacol.
, vol.16
, pp. 463-464
-
-
Silver, H.1
Geraisy, N.2
|